Phase I clinical trials and ex vivo studies conducted by Roche have demonstrated that gantenerumab can safely remove amyloid plaques from the brain of patients with Alzheimer’s disease.
Gantenerumab, an investigational fully human anti-amyloid beta monoclonal antibody will bind to amyloid plaques in the brain and remove them.
The studies also showed that gantenerumab treatment resulted in a dose-dependent reduction of brain amyloid and increase in amyloid load.
Patients are being recruited for a trial to evaluate the efficacy and safety of gantenerumab in patients in the early or prodromal stage of Alzheimer’s disease.
Luca Santarelli, global head of Roche’s neuroscience disease translational area, said that the study objective is not only intended to demonstrate the effects of gantenerumab on brain amyloid, but also to start elucidating its mechanism of action.